丙酮酸激酶M2型在恶性肿瘤中的表达及其临床检测研究进展

doi:10.3969/j.issn.1004-583X.2022.03.016

摘要/Abstract

摘要：

丙酮酸激酶M2型(PKM2)是肿瘤细胞有氧糖酵解途径的关键酶之一。它通过调节肿瘤细胞的代谢、基因表达和细胞周期进程等,与肿瘤的发生、发展、转移、复发等密切相关。在多种恶性肿瘤患者(如肺癌、胃癌、结直肠癌、乳腺癌等)的组织样本中发现,相较于癌旁组织,肿瘤组织中PKM2表达水平显著增高。PKM2高表达与患者较差的临床表现和不良预后相关。同时,PKM2伴随着肿瘤细胞的更新被释放到体液及粪便中,能够通过临床常规检验方法进行检测,可能在肿瘤筛查、诊断及预后方面起到重要作用。此外,PKM2还可作为潜在的肿瘤治疗靶点,敲除或敲减PKM2基因可以抑制肿瘤细胞的增殖、迁移及耐药,并诱导细胞凋亡。PKM2在肿瘤诊断方面的应用价值不逊于某些传统肿瘤标志物,与其他肿瘤标志物的联用或可改善癌症的早期诊断。

关键词: 丙酮酸激酶M2型, 恶性肿瘤, 诊断, 治疗, 预后

中图分类号:

R739.9

程燕妮, 刘佳, 袁野, 张德太, 王琳. 丙酮酸激酶M2型在恶性肿瘤中的表达及其临床检测研究进展[J]. 临床荟萃, 2022, 37(3): 279-284.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.03.016

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I3/279

参考文献 54

[1]	Warburg O, Wind F, Negelein E. The metabolism of tumors in the body[J]. J Gen Physiol, 1927, 8(6):519-530. doi: 10.1085/jgp.8.6.519 pmid: 19872213
[2]	Lin Y, Lv F, Liu F, et al. High expression of pyruvate kinase m2 is associated with chemosensitivity to epirubicin and 5-fluorouracil in breast cancer[J]. J Cancer, 2015, 6(11):1130-1139. doi: 10.7150/jca.12719 URL
[3]	Shiroki T, Yokoyama M, Tanuma N, et al. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism[J]. Cancer Sci, 2017, 108(5):931-940. doi: 10.1111/cas.13211 URL
[4]	Wang C, Jiang J, Ji J, et al. PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer[J]. Sci Rep, 2017, 7(1):2886. doi: 10.1038/s41598-017-03031-1 URL
[5]	Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J]. Nature, 2008, 452(7184):230-233. doi: 10.1038/nature06734 URL
[6]	Zhang Z, Deng X, Liu Y, et al. PKM2, function and expression and regulation[J]. Cell Biosci, 2019, 9:52. doi: 10.1186/s13578-019-0317-8 pmid: 31391918
[7]	Yuan C, Li Z, Wang Y, et al. Overexpression of metabolic markers PKM2 and LDH5 correlates with aggressive clinicopathological features and adverse patient prognosis in tongue cancer[J]. Histopathology, 2014, 65(5):595-605. doi: 10.1111/his.2014.65.issue-5 URL
[8]	Kurihara-Shimomura M, Sasahira T, Nakashima C, et al. The multifarious functions of pyruvate kinase M2 in oral cancer cells[J]. Int J Mol Sci, 2018, 19(10):2907. doi: 10.3390/ijms19102907 URL
[9]	Mukherjee J, Ohba S, See WL, et al. PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells[J]. Int J Cancer, 2016, 139(1):99-111. doi: 10.1002/ijc.30041 pmid: 26874904
[10]	Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13):2181-9210. doi: 10.1200/JCO.2009.26.2543 URL
[11]	Sun H, Zhu A, Zhang L, et al. Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma[J]. Int J Mol Sci, 2015, 16(10):24574-24587. doi: 10.3390/ijms161024574 URL
[12]	Guo CY, Zhu Q, Tou FF, et al. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma[J]. BMC Cancer, 2019, 19(1):289. doi: 10.1186/s12885-019-5519-2 URL
[13]	Meng MB, Wang HH, Guo WH, et al. Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo[J]. Cancer Lett, 2015, 356(2 Pt B):985-993. doi: 10.1016/j.canlet.2014.11.016 URL
[14]	Shi HS, Li D, Zhang J, et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice[J]. Cancer Sci, 2010, 101(6):1447-1453. doi: 10.1111/cas.2010.101.issue-6 URL
[15]	Wang Y, Zhao H, Zhao P, et al. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo[J]. Cancer Biomark, 2021, 32(2):221-230. doi: 10.3233/CBM-210111 URL
[16]	Fukuda S, Miyata H, Miyazaki Y, et al. Pyruvate kinase M2 modulates esophageal squamous cell carcinoma chemotherapy response by regulating the pentose phosphate pathway[J]. Ann Surg Oncol, 2015, 22(Suppl 3):S1461-1468.
[17]	Jiang M, Wu Y, Qi L, et al. Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma[J]. Chem Biol Interact, 2021, 350:109704. doi: 10.1016/j.cbi.2021.109704 URL
[18]	马素珍, 曾震军, 潘晓丽, 等. 糖酵解关键酶在结直肠癌组织中的表达及其临床意义[J]. 肿瘤, 2017, 37(7): 723-731+741.
[19]	Lu WQ, Hu YY, Lin XP, et al. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells[J]. Oncotarget, 2017, 8(27):44171-44185. doi: 10.18632/oncotarget.v8i27 URL
[20]	Li Q, Cao L, Tian Y, et al. Butyrate suppresses the proliferation of colorectal cancer cells via targeting pyruvate kinase M2 and metabolic reprogramming[J]. Mol Cell Proteomics, 2018, 17(8):1531-1545. doi: 10.1074/mcp.RA118.000752 URL
[21]	Yang P, Ding GB, Liu W, et al. Tannic acid directly targets pyruvate kinase isoenzyme M2 to attenuate colon cancer cell proliferation[J]. Food Funct, 2018, 9(11):5547-5559. doi: 10.1039/C8FO01161C URL
[22]	Li TE, Wang S, Shen XT, et al. PKM2 drives hepatocellular carcinoma progression by inducing immunosuppressive microenvironment[J]. Front Immunol, 2020, 11:589997. doi: 10.3389/fimmu.2020.589997 URL
[23]	Feng J, Wu L, Ji J, et al. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1):204. doi: 10.1186/s13046-019-1194-z URL
[24]	Feng J, Dai W, Mao Y, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1alpha/PPAR-gamma/PKM2-mediated glycolysis[J]. J Exp Clin Cancer Res, 2020, 39(1):24. doi: 10.1186/s13046-020-1528-x URL
[25]	Lu W, Cao Y, Zhang Y, et al. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer[J]. Sci Rep, 2016, 6:26351. doi: 10.1038/srep26351 URL
[26]	Hu H, Tu W, Chen Y, et al. The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients[J]. J Cancer, 2020, 11(8):2022-2031. doi: 10.7150/jca.38981 URL
[27]	James AD, Richardson DA, Oh IW, et al. Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: Role of pyruvate kinase-M2 (PKM2)[J]. Br J Cancer, 2020, 122(2):266-278. doi: 10.1038/s41416-019-0675-3 URL
[28]	Zhu Q, Hong B, Zhang L, et al. Pyruvate kinase M2 inhibits the progression of bladder cancer by targeting MAKP pathway[J]. J Cancer Res Ther, 2018, 14(Suppl):S616-S621.
[29]	Huang C, Huang Z, Bai P, et al. Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis[J]. Onco Targets Ther, 2018, 11:2075-2082. doi: 10.2147/OTT URL
[30]	Zhou H, Wang X, Mo L, et al. Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis[J]. Oncotarget, 2016, 7(17):23947-23960. doi: 10.18632/oncotarget.v7i17 URL
[31]	Wang Y, Hao F, Nan Y, et al. PKM2 inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis[J]. Int J Biol Sci, 2018, 14(13):1883-1891. doi: 10.7150/ijbs.27854 URL
[32]	Wang X, Zhang F, Wu XR. Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin[J]. Sci Rep, 2017, 7:45983. doi: 10.1038/srep45983 URL
[33]	Dey P, Son JY, Kundu A, et al. Knockdown of pyruvate kinase m2 inhibits cell proliferation, metabolism, and migration in renal cell carcinoma[J]. Int J Mol Sci, 2019, 20(22) :5622. doi: 10.3390/ijms20225622 URL
[34]	Yang GJ, Wu J, Leung CH, et al. A review on the emerging roles of pyruvate kinase M2 in anti-leukemia therapy[J]. Int J Biol Macromol, 2021, 193(Pt B):1499-1506. doi: 10.1016/j.ijbiomac.2021.10.213 URL
[35]	Huang Y, Chen LM, Xie JY, et al. High expression of PKM2 was associated with the poor prognosis of acute leukemia[J]. Cancer Manag Res, 2021, 13:7851-7858. doi: 10.2147/CMAR.S331076 URL
[36]	Gao P, Shen S, Li X, et al. Dihydroartemisinin inhibits the proliferation of leukemia cells K562 by suppressing PKM2 and GLUT1 mediated aerobic glycolysis[J]. Drug Des Devel Ther, 2020, 14:2091-2100. doi: 10.2147/DDDT.S248872 URL
[37]	He Y, Wang Y, Liu H, et al. Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance[J]. Leuk Res, 2015, 39(12):1428-1436. doi: 10.1016/j.leukres.2015.09.019 URL
[38]	Najera L, Alonso-Juarranz M, Garrido M, et al. Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma[J]. Br J Dermatol, 2019, 181(1):114-127. doi: 10.1111/bjd.2019.181.issue-1 URL
[39]	Liu ZX, Hong L, Fang SQ, et al. Overexpression of pyruvate kinase M2 predicts a poor prognosis for patients with osteosarcoma[J]. Tumour Biol, 2016, 37(11):14923-14928. doi: 10.1007/s13277-016-5401-7 URL
[40]	赵晓莹. 联合检测血浆中PKM2和CEA在人结肠癌中的临床价值[J]. 中国现代药物应用, 2018, 12(12):31-32.
[41]	Kumar Y, Gurusamy K, Pamecha V, et al. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis[J]. Pancreas, 2007, 35(2):114-119. doi: 10.1097/mpa.0b013e3180537237 URL
[42]	Liu W, Woolbright BL, Pirani K, et al. Tumor M2-PK: A novel urine marker of bladder cancer[J]. PLoS One, 2019, 14(6):e0218737. doi: 10.1371/journal.pone.0218737 URL
[43]	Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer[J]. Br J Cancer, 2004, 91(5):980-984. doi: 10.1038/sj.bjc.6602033 URL
[44]	蔡尚霞, 姜海英, 杨浩. 宫颈、阴道分泌物和血清PKM2检测在子宫内膜癌、宫颈癌诊断中的意义[J]. 中国实验诊断学, 2020, 24(4):622-623.
[45]	Guan M, Tong Y, Liu X, et al. Enzyme kinetic assay to measure the activity of tumor M2 pyruvate kinase in breast cancer patients[J]. Ann Clin Lab Sci, 2017, 47(6):676-686.
[46]	Croner LJ, Dillon R, Kao A, et al. Discovery and validation of a colorectal cancer classifier in a new blood test with improved performance for high-risk subjects[J]. Clin Proteomics, 2017, 14:28. doi: 10.1186/s12014-017-9163-z URL
[47]	Wang D, Li C, Zhu Y, et al. TEPP-46-based AIE fluorescent probe for detection and bioimaging of PKM2 in living cells[J]. Anal Chem, 2021, 93(37):12682-12689. doi: 10.1021/acs.analchem.1c02529 URL
[48]	Beinat C, Haywood T, Chen YS, et al. The utility of [(18)F]DASA-23 for molecular imaging of prostate cancer with positron emission tomography[J]. Mol Imaging Biol, 2018, 20(6):1015-1024. doi: 10.1007/s11307-018-1194-y URL
[49]	Fung KY, Tabor B, Buckley MJ, et al. Blood-based protein biomarker panel for the detection of colorectal cancer[J]. Plos One, 2015, 10(3):e0120425. doi: 10.1371/journal.pone.0120425 URL
[50]	Kaura B, Bagga R, Patel FD. Evaluation of the pyruvate kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma[J]. J Obstet Gynaecol Res, 2004, 30(3):193-196. doi: 10.1111/jog.2004.30.issue-3 URL
[51]	Landt S, Jeschke S, Koeninger A, et al. Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer[J]. Anticancer Res, 2010, 30(2):375-381.
[52]	苏鹏, 陈海洋. 非小细胞肺癌患者血浆PKM2检测的临床意义[J]. 河北医药, 2017, 39(11):1623-1626.
[53]	Parente F, Marino B, Ilardo A, et al. A combination of faecal tests for the detection of colon cancer: A new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study[J]. Eur J Gastroenterol Hepatol, 2012, 24(10):1145-1152. doi: 10.1097/MEG.0b013e328355cc79 URL
[54]	van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: A systematic review[J]. Eur Urol, 2005, 47(6):736-748. pmid: 15925067

丙酮酸激酶M2型在恶性肿瘤中的表达及其临床检测研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 54

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	金鑫, 吴金玲, 尹丽丽. 持续性植物状态促醒机制及治疗研究进展[J]. 临床荟萃, 2024, 39(2): 172-176.
[3]	王琦, 陈宏. 维生素D在支气管哮喘和慢性阻塞性肺疾病治疗中的应用进展[J]. 临床荟萃, 2024, 39(1): 88-91.
[4]	赵旭辉, 黄小敏, 达德转, 许焱, 崔晓东, 李红玲. 基于生物信息学筛选影响胃癌患者预后的糖酵解相关基因[J]. 临床荟萃, 2024, 39(1): 20-29.
[5]	刘丽丽, 袁宇婷, 赖耿良, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病第15天微小残留与预后的关系[J]. 临床荟萃, 2024, 39(1): 47-52.
[6]	崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74.
[7]	邹子良, 余海, 王迪, 褚泰运, 李驹, 钱宝堂. 冠状动脉慢性完全闭塞病变介入治疗研究现状[J]. 临床荟萃, 2024, 39(1): 80-83.
[8]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[9]	赵浩天, 李丽. 肺超声在心脏急重症疾病合并肺水肿中应用的研究进展[J]. 临床荟萃, 2023, 38(9): 832-837.
[10]	王鑫, 张展, 刘铎, 谢萍. 铁缺乏与肺动脉高压相关性的研究进展[J]. 临床荟萃, 2023, 38(9): 838-844.
[11]	陈聪水, 李园, 陈淑芳. 重视儿童胆源性胰腺炎的中西医诊治(附1例分析)[J]. 临床荟萃, 2023, 38(8): 726-730.
[12]	武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.
[13]	侯有玲, 李奕, 关红玉, 罗红霞. 目标导向液体治疗在脑肿瘤切除术中应用效果的meta分析[J]. 临床荟萃, 2023, 38(8): 686-693.
[14]	王玥, 陈辉, 岑奕, 张哲, 张欣, 李宗锡, 陈珍珍, 贾彤彤, 章美玲. 超声引导下侧入路颈脊神经后支三氧联合注射松解治疗颈脊神经后支源性慢性颈肩痛[J]. 临床荟萃, 2023, 38(8): 714-718.
[15]	王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612.